Full Press Release Details
Sinovac Reports Unaudited Fourth Quarter and Preliminary
Full Year 2011 Financial Results
- Conference call scheduled for Thursday, March 29, 2012 at
BEIJING, March 29, 2012 /PRNewswire-Asia/ -- Sinovac Biotech
Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited fourth quarter and
preliminary full year financial results for the period ended December 31, 2011.
Financial Highlights
| Sales in the fourth quarter 2011 increased 131.3% year-over-year to $21.1 million, compared to $9.1 million, and full year sales increased 70.2% to $56.8 million. | ||
| Net income attributable to stockholders in the fourth quarter 2011 was $2.8 million, or $0.05 per basic and diluted share. Full year net loss attributable to stockholders was $845,000, or $0.02 per basic and diluted share. | ||
| Operating cash flow in the fourth quarter was $16.6 million, up 40.6% compared to $11.8 million in the same period of last year. Compared to a cash outflow of $14.3 million in 2010, operating cash inflow in 2011 was $13.9 million. | ||
| Cash and cash equivalents and short-term investments with guaranteed income totaled $104.3 million as of December 31, 2011, compared to $94.2 million as of September 30, 2011 and $103.1 million as of December 31, 2010. |
Recent Business Highlights
| In January 2012, Sinovac commenced the phase III clinical trial for its proprietary inactivated EV71 vaccine against hand, foot and mouth disease (HFMD). According to the results of phase II clinical trial completed in November 2011, the formulation of 400U with aluminum adjuvant was selected as the dosage to be evaluated in the Phase III clinical trial. The trial is expected to enroll up to 10,000 healthy volunteers from ages 6-35 months, and designed as a randomized, double blinded, placebo controlled study. The vaccination schedule calls for two shots at 0 and 28 days. Up to present time, approximately 10,000 healthy volunteers have been enrolled. Recently, the two-shot inoculation schedule and the blood collection on the 56 th day after the first inoculation were completed. Starting on March 14, 2012, the observation and data collection phase to assess the HFMD epidemic situation has commenced to evaluate the efficacy of the novel vaccine. Currently, the Phase III trial is on track to be completed in the first half of 2013. | ||
| In December 2011, Sinovac Dalian, an operating subsidiary of the Company obtained the production license from the SFDA for its mumps vaccine. Subsequently in March 2012, Sinovac Dalian, applied for the GMP certification for the mumps vaccine production plant and currently is waiting for notification of the inspection date from the SFDA. | ||
| In October 2011, the Company purchased an additional 1.53% interest in Sinovac Beijing by contributing a total amount of $2.9 million (RMB 18.6 million) in declared but unpaid dividends and increased its equity ownership from 71.56% to 73.09%. | ||
| In March 2012, Sinovac was awarded the government tender in Mongolia to supply Healive to Mongolia. The total ordered quantity is approximately 191,000 doses. |
Dr. Weidong Yin, Chairman, President and CEO of Sinovac, commented,
"I am very pleased with our sales performance this year, especially for Bilive, which has been instrumental in expanding our
private market share and increasing our revenue from private market in China. In 2011, we have gained traction in the public
market and won tenders in Xinjiang Uyghur Autonomous Region, Shanghai and Beijing. While the Chinese vaccine market is recovering
from unfavorable factors that occurred in 2010, we have nonetheless expanded our sales to overseas markets. We are now exporting
vaccines to Mongolia, Nepal and the Philippines, and we focused on entering Mexico in 2012, subject to receipt of requisite local
market clearance. In 2012, our sales team will continue its efforts to execute its sales strategies to expand existing commercialized
vaccine products and we expect both of our animal rabies vaccine and mumps vaccine to contribute revenue to the Company this year."
Dr. Yin continued, "We are committed to advancing the development
of our vaccine pipeline. Since there is no EV71 specific prevention method to help control the spread of HFMD, our development
of this vaccine addresses a significant unmet medical need as recognized by the governments and parents across Asia. As such,
advancing the clinical development of our proprietary EV71 vaccine is our highest priority program. Following the positive
results from phase I and phase II clinical trials for our EV71 vaccine in 2011, we commenced the phase III clinical trial in January
2012. We have enrolled approximately 10,000 healthy volunteers, and completed the two shot inoculation schedule and the blood
samples collection on the 56th days after the first shot. We are collecting the epidemic situation data surrounding
the clinical site and this data will be utilized to assess the vaccine's efficacy. We anticipate completing the clinical
trial in the first half of 2013. Meanwhile, the construction of a dedicated EV71 vaccine production plant is progressing
on schedule at our Changping site in Beijing."
Dr. Yin concluded, "In addition to improving our operating
efficiencies, we continue to manage proactively our strong cash position, which provides ample resources to support our near-term
R&D programs and production capacity expansion for our new vaccines. We are prudently investing in future growth for
the long-term interest of our shareholders. "
Financial Review for Fourth Quarter Ended December 31, 2011
Sales Revenue and Gross Profit
Sales for the fourth quarter 2011 were $21.1 million, up 131.3%
from $9.1 million for the fourth quarter of 2010. The increase of the fourth quarter 2011 sales mainly comes from the recognition
of $14 million revenue of H1N1 vaccine, and the increased sales of Bilive in the private market.
An analysis of gross profit is as follows:
| Three months ended December 31, | ||||||||||||||||
| 2011 | 2010 | |||||||||||||||
| $ | % of Revenue | $ | % of Revenue | |||||||||||||
| Sales | ||||||||||||||||
| Hepatitis vaccines | $ | 3,576,426 | 17 | % | $ | 2,007,117 | 22 | % | ||||||||
| Influenza vaccines | 17,566,978 | 83 | % | 7,134,463 | 78 | % | ||||||||||
| Total sales | 21,143,404 | 100 | % | 9,141,580 | 100 | % | ||||||||||
| Cost of sales | 8,031,758 | 38 | % | 11,028,661 | 121 | % | ||||||||||
| Gross profit (loss) | $ | 13,111,646 | 62 | % | $ | (1,887,081 | ) | (21 | )% |
Compared to the same period of 2010, the increased gross profit
margin in the fourth quarter 2011 was mainly attributed to the reduced inventory write-offs and provisions and more revenue recognized
on government stockpiled H1N1 vaccines that expired and passed inspection. The Company recorded a $2.74 million inventory provision
in the fourth quarter 2011 as cost of sales to reflect the expiration of their shelf lives of 581,000 doses of seasonal influenza
vaccines due to ending of the flu season, and 2.03 million doses of Healive and Bilive that may not likely be sold in 2012. The
gross margin also reflected a 10% sales return provision for 2011 sales of Anflu and an 8.3% provision for Healive and Bilive.
After deducting depreciation of land use rights, amortization
of licenses and permits, the gross margin was a positive 61.9% and a negative 23.2% for the fourth quarter of 2011 and 2010, respectively.
Selling, general and administrative expenses for the fourth
quarter 2011 decreased compared to the same period in 2010. The decrease in general expenses mainly resulted from cost control.
The decrease in selling expenses was mainly due to improved productivity of our sales team and less handling and transportation
fees on government stockpiling orders which did not require shipment.
Excluding pandemic flu vaccine sales, SG&A expenses as a
percentage of sales was 83.2% and 176.1% for the current quarter and prior year quarter, respectively.
Due to the more effective credit management implemented in 2011,
the provision for doubtful accounts for the fourth quarter 2011 was reversed by $1.7 million, compared to an increase of $1.9 million
for the same period in prior year.
The R&D expenses in the fourth quarter of 2011 were primarily
allocated to the continued development of the pipeline vaccines, including the expenses for the EV71 vaccine with its phase II
clinical trial completed in November 2011, the trial production of the mumps vaccine and other R&D projects.
Depreciation of property, plant and equipment and amortization
of license and permits for the fourth quarter 2011 were $365,000, lower than $525,000 for the same period of last year, primarily
because of the expiration of the amortization period of inactivated hepatitis vaccines.
Total operating expenses for the fourth quarter of 2011 were
$6.3 million, compared to $11.3 million in the comparative period in 2010.
Operating income for the three months ended December 31, 2011
was $6.8 million, compared to an operating loss of $13.2 million for the same period of the prior year. Net income attributable
to stockholders for the fourth quarter of 2011 was $2.8 million, or $0.05 per diluted share, as compared to a net loss attributable
to stockholders of $8.9 million, or $0.17 per diluted share, in the same period of 2010.
Financial Review for the Twelve Months Period Ended December
Sales Revenue and Gross Profit
Annual sales in 2011 were $56.8 million, up 70.2% from $33.4
million in 2010. During 2011, $21.8 million in pandemic influenza vaccine sales relating to a prior year order were recorded.
The increase in the regular (non-pandemic) vaccine sales was driven by the significant growth in Bilive sales to the private
Sales of our H1N1 and H5N1 vaccines, Panflu.1 and Panflu, represented
24.6% and 13.7%, respectively, of total sales in 2011, as compared to 21.5% and 7.2% of total sales for 2010. The H1N1 and
H5N1 vaccines were all ultimately sold to the Chinese government.
An analysis of our gross profit is as follows:
| Twelve months ended December 31, | ||||||||||||||||
| 2011 | 2010 | |||||||||||||||
| $ | % of revenue | $ | % of revenue | |||||||||||||
| Sales | ||||||||||||||||
| Hepatitis vaccines | $ | 26,939,386 | 47 | % | $ | 16,200,844 | 49 | % | ||||||||
| Influenza vaccines | 29,902,506 | 53 | % | 17,200,582 | 51 | % | ||||||||||
| Total sales | 56,841,892 | 100 | % | 33,401,426 | 100 | % | ||||||||||
| Cost of sales | 21,127,410 | 37 | % | 16,718,727 | 50 | % | ||||||||||
| Gross profit | $ | 35,714,482 | 63 | % | $ | 16,682,699 | 50 | % |
As coordination of production planning improved in 2011, inventory
write-offs and provisions decreased from $6.8 million in 2010 to $4.0 million in 2011, which yielded a higher gross profit margin
compared to 2010. However, the lowered inventory write-offs and provisions were not totally reflected in the gross margin
increase, given that the positive effect was partially offset by a higher write-off of idle capacity being included in cost of
sales, which rose from $298,000 in 2010 to $1.2 million in 2011. In 2011, due to the enhanced control of production volume,
hepatitis and the influenza production facilities had idle capacity of 48% and 30%, respectively. In 2010, the idle capacity
of hepatitis plant was only 11%.
After deducting depreciation of land-use rights, amortization
of licenses, permits, gross margins were 62.3% and 48.3% for 2011 and 2010, respectively.
Selling general and administrative expenses increased in 2011,
but by much less proportionately than the increase in sales. In 2011, the Company has realigned its sales and marketing efforts
to better address the changing Chinese vaccine market. Selling expenses increased as a result of increased sales promotional
expenses for selling Bilive in the private market, expanded sales team to cover a wider geographic area, and increased compensation
to sales professionals to improve employee retention. General and administrative expenses remained at about the same level
Sinovac implemented a more effective credit management in 2011.
As a result, we recorded a recovery of doubtful accounts of $167,000 in 2011, compared to an expense of $1.9 million in 2010.
Over the last few years, the Company has placed a much greater
emphasis on product development and built a strong pipeline for the future. R&D expenses for 2011 were $9.0 million,
compared to $8.5 million in 2010. R&D expenses in 2011 were primarily related to completing the phase II clinical trial
and phase III trial production for the Company's EV71 vaccine product candidate, and trial production of mumps vaccine and completing
the development of the animal rabies vaccine.
Depreciation of property, plant and equipment and amortization